Lopinavir and Ritonavir Tablets: A Resilient Herald in Antiretroviral Therapy

Lopinavir ritonavir (commonly branded as Kaletra®) has stood the test of time as a dual protease inhibitor combination, delivering reliable antiviral potency in the fight against HIV As one of the earlier fixed-dose combinations in antiretroviral therapy, its carefully calibrated mixture uses ritonavir primarily to boost lopinavir’s levels—enhancing efficacy with effective dose sparing. Consequently, patients have benefited from potent viral suppression, largely manageable side effects, and a solid place in treatment guidelines, especially for individuals needing robust early intervention or limited access to newer options. Furthermore, lopinavir ritonavir tablets retain importance in specific contexts, such as resource-limited settings, pregnancy, and cases of drug resistance. Its well-characterized interactions, decade-long observational data, and standardized dosing contribute to its continued acceptance. In this review, we explore the full scope of its pharmacology, clinical performance, patient-centered metrics, and global significance—ultimately reaffirming why lopinavir ritonavir remains a trusted component of HIV therapy.